BeyondSpring faces a tough winter as FDA rejects its lead drug
BeyondSpring’s hopes of an early Christmas gift from the FDA were dashed today after the regulator said it was unable to approve the company’s lead […]
BeyondSpring’s hopes of an early Christmas gift from the FDA were dashed today after the regulator said it was unable to approve the company’s lead […]
In an interview with PharmaShots, Dr. Trevor Feinstein (Hematology Specialist in Fayetteville, GA) and Dr. Lan Huang (Co-founder, Chairman, and CEO at BeyondSpring) shared their views on the […]
Shots: Wanchunbulin to receive $30M up front, $170M as regulatory and sales milestone & is eligible to receive $15M as equity investment at a pre-money […]
Shots: The P-III DUBLIN-3 trial evaluates plinabulin + docetaxel vs docetaxel alone in 599 patients with 2L & 3L NSCLC EGFR wild type, with measurable […]
Shots: The P-III PROTECTIVE-1 study assessing plinabulin as monothx vs Pegfilgrastimfor in patients with CIN. The US FDA accepted the NDA & PR and the […]
Shots: The NDA submission is based on data from P-III PROTECTIVE-2 study evaluating Plinabulin + Neulasta vs Neulasta alone for the prevention of CIN The […]
Copyright © 2024 | WordPress Theme by MH Themes